- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.11. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| ZEO SCIENTIFIX Aktie jetzt für 0€ handeln | |||||
| 03.11. | Zeo ScientifiX, Inc.: ZEO ScientifiX Makes Industry History as First Facility to Achieve AABB's Newly Established Quality Management Systems Certification | 211 | ACCESS Newswire | Landmark industry-first certification reinforces ZEO's leadership in manufacturing quality, independent oversight, and the rapidly expanding U.S. regenerative medicine industry. FORT LAUDERDALE, FL... ► Artikel lesen | |
| 30.10. | Pluri geht Partnerschaft mit ZEO ScientifiX ein und kündigt Eigenkapitalfinanzierung an | 4 | Investing.com Deutsch | ||
| 26.10. | Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform | 4 | Insider Monkey | ||
| 26.10. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.10. | BODYWELLE Announces Exclusive Use of ZEO ScientifiX Biologics for Pain, Joints, and Wound Care Treatments | 461 | ACCESS Newswire | The Miami Beach practice now uses quantified stem cell and extracellular vesicle products, along with an autologous option derived from the patient's own platelets. MIAMI BEACH, FL / ACCESS Newswire... ► Artikel lesen | |
| 15.09. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.09. | Zeo ScientifiX, Inc.: ZEO ScientifiX Plans Expansion into Georgia and Tennessee as New Regenerative Medicine Laws Take Effect | 8.813 | ACCESS Newswire | Company looks to broaden its Southeast presence to support healthcare providers navigating newly enacted state laws providing for certain stem cell and regenerative medicine therapies. FORT LAUDERDALE... ► Artikel lesen | |
| 14.09. | Zeo ScientifiX, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 01.09. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.09. | Zeo ScientifiX, Inc.: ZEO ScientifiX Announces Multidisciplinary Expert Faculty Lineup for the ZEO Xperience | 346 | ACCESS Newswire | Leading physicians, scientists, regulatory experts, and healthcare innovators will convene October 23-25 at Fort Lauderdale's Pier Sixty-Six Resort + Marina for three days of regenerative medicine education... ► Artikel lesen | |
| 04.08. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.08. | Zeo ScientifiX, Inc.: ZEO ScientifiX Launches First-of-Its-Kind ZEO Xperience, a Three-Day Immersive Regenerative Medicine Experience for Healthcare Professionals | 259 | ACCESS Newswire | Hosted at Fort Lauderdale's newly reimagined Pier Sixty-Six Resort, the inaugural event combines cutting-edge biologics education, hands-on clinical training, practice growth strategies, and latest... ► Artikel lesen | |
| 24.07. | Zeo ScientifiX, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 21.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX Strengthens South Florida's Growing Biotechnology Ecosystem Through Regenerative Medicine Innovation | 363 | ACCESS Newswire | Operating from Nova Southeastern University's Center for Collaborative Research, ZEO ScientifiX is expanding physician education, scientific collaboration, and regenerative biologic innovation as Florida... ► Artikel lesen | |
| 08.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX Reports Strong Revenue Growth for Three Months and Six Months Ended April 30, 2026 | 418 | ACCESS Newswire | Company reports revenue growth of 124.6% for the quarter ended April 30, 2026 and 79.9% for the six months ended April 30, 2026, as compared to the same periods one year earlier as commercial momentum... ► Artikel lesen | |
| 01.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX to Host Live Educational Webinar for Healthcare Professionals Exploring the Southeast Regenerative Medicine Revolution | 450 | ACCESS Newswire | "One Year Later, Three States Stronger" program will examine lessons learned from Florida's first year into their pioneering stem cell law and provide physicians from other states an insight of what... ► Artikel lesen |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| JANUX THERAPEUTICS | 12,040 | 0,00 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 | ||
| RECURSION PHARMACEUTICALS | 3,550 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? |
Das Unternehmen ZEO SCIENTIFIX INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZEO SCIENTIFIX INC finden Sie auf Wallstreet Online.